Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects
Teratology · 1988-08 · 38 (2) · 135-144
DOI: 10.1002/tera.1420380206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Teratology, 2005-06. Verfasst von J L Yovich und 2 weiteren Autor:innen. Beteiligte Einrichtung: PIVET Medical Centre, Perth, Western Australia. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Medroxyprogesterone acetate (MPA; Provera) was given orally to 449 women from the 5th to 7th week of pregnancy until at least the 18th week. Data are recorded from two treatment groups (recurrent abortion and threatened abortion) and are compared to a matched series. A total of 1,016 pregnancies are included in the study, and all patients were recruited from a subfertile population conceiving from a range of infertility treatments. Early pregnancy wastage was high throughout the groups and was significantly elevated (43%; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PIVET Medical Centre, Perth, Western Australia.
Zitieren
APA
Yovich, J. L., Turner, S. R., & Draper, R. (1988). Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology, 38(2), 135-144. https://doi.org/10.1002/tera.1420380206
Vancouver
Yovich JL, Turner SR, Draper R. Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects. Teratology. 1988;38(2):135-144. doi:10.1002/tera.1420380206
BibTeX
@article{Yovich1988,
author = {Yovich, J L and Turner, S R and Draper, R},
title = {Medroxyprogesterone acetate therapy in early pregnancy has no apparent fetal effects},
journal = {Teratology},
year = {1988},
volume = {38},
number = {2},
pages = {135--144},
doi = {10.1002/tera.1420380206}
}
EUVIMED